NCT06882876View on ClinicalTrials.gov

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

July 30, 2029

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

JS014 Combined With Toripalimab and TACE

JS014 (60μg/kg,QW)+Toripalimab (240mg , Q3W)+ dTACE (60mg/m2)

Trial Locations (1)

Unknown

Xiangya Hospital, Changsha

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Xiangya Hospital of Central South University

OTHER